BACKGROUND: Cystic fibrosis (CF) affects the lungs causing infections and inflammation. Surfactant protein D (SP-D) is an innate defense lectin primarily secreted in the lungs. We investigated the influence of the SP-D Met11Thr polymorphism on CF lung function; and serum SP-D as a marker for CF lung disease. METHODS: For 107 CF patients (73 children, and 34 adults) serum SP-D and SP-D Met11Thr genotype were available. Leukocyte count was obtained for a subset of patients. Lung function was measured as forced expiratory volume in one second (FEV-1). RESULTS: Serum SP-D was increased in CF patients compared to healthy controls, positively correlated to leukocyte count, and negatively correlated to FEV-1. We found no correlation between SP-D Met11Thr genotype and FEV-1, and we found corresponding genotype frequencies in CF patients and in healthy controls. CONCLUSION: Serum SP-D in CF patients was increased in parallel with leukocyte count and with reduced FEV-1 and may constitute an alternative biomarker for lung disease, in the clinical setting and in research. Copyright 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
BACKGROUND:Cystic fibrosis (CF) affects the lungs causing infections and inflammation. Surfactant protein D (SP-D) is an innate defense lectin primarily secreted in the lungs. We investigated the influence of the SP-DMet11Thr polymorphism on CF lung function; and serum SP-D as a marker for CF lung disease. METHODS: For 107 CFpatients (73 children, and 34 adults) serum SP-D and SP-DMet11Thr genotype were available. Leukocyte count was obtained for a subset of patients. Lung function was measured as forced expiratory volume in one second (FEV-1). RESULTS: Serum SP-D was increased in CFpatients compared to healthy controls, positively correlated to leukocyte count, and negatively correlated to FEV-1. We found no correlation between SP-DMet11Thr genotype and FEV-1, and we found corresponding genotype frequencies in CFpatients and in healthy controls. CONCLUSION: Serum SP-D in CFpatients was increased in parallel with leukocyte count and with reduced FEV-1 and may constitute an alternative biomarker for lung disease, in the clinical setting and in research. Copyright 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Authors: Chang-Jiang Guo; Elena N Atochina-Vasserman; Elena Abramova; Ley Cody Smith; Michael F Beers; Andrew J Gow Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-08-14 Impact factor: 5.464
Authors: David A Ngan; Pearce G Wilcox; May Aldaabil; Yuexin Li; Jonathon A Leipsic; Don D Sin; S F Paul Man Journal: BMC Pulm Med Date: 2012-02-14 Impact factor: 3.317
Authors: Preston E Bratcher; Nathaniel M Weathington; Heidi J Nick; Patricia L Jackson; Robert J Snelgrove; Amit Gaggar Journal: PLoS One Date: 2012-07-30 Impact factor: 3.240
Authors: Veronica Marcos; Zhe Zhou-Suckow; Ali Önder Yildirim; Alexander Bohla; Andreas Hector; Ljubomir Vitkov; Wolf Dietrich Krautgartner; Walter Stoiber; Matthias Griese; Oliver Eickelberg; Marcus A Mall; Dominik Hartl Journal: Mediators Inflamm Date: 2015-03-31 Impact factor: 4.711